首页> 外文期刊>Health Research Policy and Systems >From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries
【24h】

From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries

机译:从市场准入到患者准入:36个欧洲国家/地区基于证据的药品报销和定价方法概述

获取原文
           

摘要

Background Coverage decisions determining the benefit baskets of health systems have been increasingly relying on evidence regarding patient benefit and costs. Relevant structures, methodologies, and processes have especially been established for pharmaceuticals but approaches differ. The objective of this work was thus to identify institutions in a broad range of European countries (n?=?36) in charge of determining the value of pharmaceuticals for pricing and reimbursement purposes and to map their decision-making process; to examine the different approaches and consider national and supranational possibilities for best practice. Methods Institutions were identified through websites of international networks, ministries, and published literature. Details on institutional practices were supplemented with information from institution websites and linked online sources. Results The type and extent of information available varied considerably across countries. Different types of public regulatory bodies are involved in pharmaceutical coverage decisions, assuming a range of responsibilities. As a rule, the assessment of scientific evidence is kept structurally separate from its appraisal. Recommendations on value are uniformly issued by specific committees within or commissioned by responsible institutions; these institutions often also act as decision-makers on reimbursement status and level or market price. While effectiveness and costs are important criteria in all countries, the latter are often considered on a case-by-case basis. In all countries, manufacturer applications, including relevant evidence, are used as one of the main sources of information for the assessment. Conclusion Transparency of evidence-based coverage decisions should be enhanced. International collaboration can facilitate knowledge exchange, improve efficiency of information production, and strengthen new or developing systems.
机译:背景技术确定医疗系统福利篮子的承保范围决策越来越依赖于有关患者福利和成本的证据。有关药物的结构,方法和过程已特别确定,但方法有所不同。因此,这项工作的目的是确定欧洲许多国家(n = 36)的机构,这些机构负责确定用于定价和报销目的的药品价值,并确定其决策过程;研究不同的方法,并考虑最佳实践的国家和超国家可能性。方法通过国际网络,政府部门和公开文献网站确定机构。有关机构做法的详细信息得到了机构网站和在线链接资源的补充。结果各国可获得的信息的类型和程度差异很大。承担一系列责任,不同类型的公共监管机构参与药物覆盖率决策。通常,科学证据的评估在结构上与评估分开。价值建议由负责机构内部的特定委员会统一发布或委托其负责;这些机构通常还充当报销状态,水平或市场价格的决策者。尽管有效性和成本是所有国家的重要标准,但通常会逐案考虑后者。在所有国家/地区,制造商的申请(包括相关证据)被用作评估的主要信息来源之一。结论应提高基于证据的覆盖范围决策的透明度。国际合作可以促进知识交流,提高信息生产效率,并加强新的或发展中的系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号